Pozzilli, Paolo <br/><br/>
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).  [electronic resource] 

 -  Diabetes, obesity & metabolism  07 2017 
 - 1024-1031 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12937  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Diabetes Mellitus, Type 2--blood<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Monitoring<br/>Drug Resistance<br/>Drug Therapy, Combination<br/>Female<br/>Glucagon-Like Peptide-1 Receptor--antagonists & inhibitors<br/>Glucagon-Like Peptides--administration & dosage<br/>Glycated Hemoglobin--analysis<br/>Humans<br/>Hyperglycemia--prevention & control<br/>Hypoglycemia--chemically induced<br/>Hypoglycemic Agents--administration & dosage<br/>Immunoglobulin Fc Fragments--administration & dosage<br/>Incretins--administration & dosage<br/>Injections, Subcutaneous<br/>Insulin Glargine--administration & dosage<br/>Intention to Treat Analysis<br/>Male<br/>Middle Aged<br/>Patient Dropouts<br/>Recombinant Fusion Proteins--administration & dosage